China
Africa
Explore chapters and articles related to this topic
Phenotypic Heterogeneity of the Dermal Monocyte/Macrophage System
Published in Brian J. Nickoloff, Dermal Immune System, 2019
Wolfram Sterry, Wolf-Henning Boehncke
Cutaneous T cell lymphomas of low-grade malignancy, such as mycosis fungoides, Sézary’s syndrome, or pleomorphic T cell lymphoma, small and medium type, are characterized by an increase of T cell-associated macrophages, showing their typical dendritic morphology, phenotype (CD1a−, Leu-M5high, Ki-M1low, Ki-M6low, Ki-M8low), perivascular localization, and absence from intervascular areas also in these conditions. The T cell-associated macrophages are more frequent than Langerhans cells which are known to be increased in cutaneous T cell lymphomas.55
Lymphocyte homing and immunology of extranodal lymphoid tissues
Published in Franco Cavalli, Harald Stein, Emanuele Zucca, Extranodal Lymphomas, 2008
Mariagrazia Uguccioni, James J Campbell, Katrin Kuscher, Marshall E Kadin
The World Health Classification of Tumors of Hematopoietic and Lymphoid Tissues recognizes cutaneous T-cell lymphomas, leukemic/disseminated NK/T-cell lymphomas, other extranodal NK/T-cell lymphomas, and several types of nodal T-cell lymphomas, including angioimmunoblastic T-cell lymphoma (AILD), anaplastic T-cell lymphoma (ALCL), and peripheral T-cell lymphoma, unspecified (PTCL-U) (WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, Lyon, 2001). The latter category includes T-zone lymphoma, lymphoepithelioid (Lennert’s) lymphoma, pleomorphic T-cell lymphoma, small, medium, and large cell types, and T-immunoblastic lymphoma. As might be expected, the localization of tumor cells to lymph nodes, gut, skin, and other extranodal sites is largely determined by the homing receptors on the tumor cells and their ligands expressed on the vascular endothelium of the target organs (Table 5.1). The following section will summarize the literature on this subject.
Overall survival and registration of cutaneous T-cell lymphoma patients in Sweden: a multi-center cohort and validation study
Published in Acta Oncologica, 2022
Julia Nenonen, Anna H. Winther, Ellinor Leijonhufvud, Emma Belfrage, Karin E. Smedby, Hanna Brauner
The final study population consisted of 127 patients (KUH: n = 101; UUH: n = 26). The patients were categorized in two subgroups based on the CTCL subtype: MF and SS (n = 97, of which 89 MF and 8 SS) and other CTCLs (n = 30) (Table 1). The group of other CTCLs included patients that were diagnosed with primary cutaneous anaplastic large cell lymphoma (n = 11); primary cutaneous CD4+ small/medium T-cell lymphoma (n = 7); cutaneous lymphomas not otherwise specified (n = 7); primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma (n = 2); primary cutaneous peripheral T-cell lymphoma, unspecified (n = 2); cutaneous CD4+ pleomorphic T-cell lymphoma (n = 1). The median age at diagnosis was 67 years for both MF and SS patients and other CTCLs. The male to female ratio was 1.5:1 in all CTCLs, 1.6:1 in MF and SS and 1.3:1 in other CTCLs.
Efficacy of doxycycline in the treatment of early stages of mycosis fungoides: a randomized controlled trial
Published in Journal of Dermatological Treatment, 2021
H. El Sayed, S. Shalaby, M. R. E. Abdel-Halim, D. M. Aboelfadl, N. Samir
The lack of satisfactory therapeutic efficacy in this study compared to the successful treatment of a case of primary cutaneous CD4+ small/medium-sized pleomorphic T cell lymphoma, after 6 weeks of 200 mg doxycycline daily therapy can be explained by the current understanding of this type of T cell proliferation which was downgraded in the current WHO classification of hematological malignancies to just a lymphoproliferative disorder not an actual lymphoma based on limited clinical risk, localized disease and similarity to clonal drug reactions (28,55). And so, doxycycline seems to have acted mainly in this case as an anti-inflammatory agent.